TriSalus Life Sciences, Inc. (NASDAQ:TLSI) CEO Mary T. Szela Purchases 5,030 Shares

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) CEO Mary T. Szela bought 5,030 shares of the business’s stock in a transaction that occurred on Wednesday, January 29th. The shares were acquired at an average price of $5.03 per share, with a total value of $25,300.90. Following the completion of the transaction, the chief executive officer now directly owns 439,249 shares of the company’s stock, valued at $2,209,422.47. This trade represents a 1.16 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

TriSalus Life Sciences Stock Performance

TLSI stock opened at $5.11 on Friday. TriSalus Life Sciences, Inc. has a 1-year low of $3.50 and a 1-year high of $10.42. The business has a 50 day simple moving average of $4.59 and a two-hundred day simple moving average of $4.75.

Institutional Trading of TriSalus Life Sciences

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Geode Capital Management LLC grew its position in shares of TriSalus Life Sciences by 45.4% during the third quarter. Geode Capital Management LLC now owns 200,427 shares of the company’s stock valued at $924,000 after purchasing an additional 62,542 shares in the last quarter. MSD Partners L.P. purchased a new position in TriSalus Life Sciences during the 3rd quarter valued at approximately $184,000. Vestcor Inc bought a new stake in TriSalus Life Sciences in the 3rd quarter worth approximately $108,000. Virtu Financial LLC purchased a new stake in shares of TriSalus Life Sciences during the 3rd quarter worth approximately $92,000. Finally, Walleye Capital LLC bought a new position in shares of TriSalus Life Sciences during the 3rd quarter valued at approximately $66,000. 2.58% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

TLSI has been the topic of several analyst reports. Roth Capital upgraded shares of TriSalus Life Sciences to a “strong-buy” rating in a research note on Monday, November 11th. Roth Mkm reiterated a “buy” rating and set a $11.00 target price on shares of TriSalus Life Sciences in a research report on Friday, January 24th. Cantor Fitzgerald initiated coverage on TriSalus Life Sciences in a report on Tuesday, December 17th. They set an “overweight” rating and a $10.00 price target for the company. Canaccord Genuity Group decreased their price objective on TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating on the stock in a research note on Friday, November 15th. Finally, Northland Securities initiated coverage on TriSalus Life Sciences in a research note on Friday, October 25th. They set an “outperform” rating and a $12.50 price objective for the company. Seven equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $11.79.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.